{"success":true,"data":{"pressRelease":{"id":"155551","rtpr_id":"nGNX604n8k-20260929","ticker":"ARQT","exchange":"NASDAQ","all_tickers":["ARQT"],"title":"Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options","author":"Globe Newswire","published_at":"2026-09-29T13:15:00.224Z","article_body":"* Simone Biles opens up about her experience managing the symptoms of these\nconditions and encourages long-term control of skin health\n* Biles’ treatment, ZORYVE(®) (roflumilast), is the #1 prescribed branded\ntopical therapy for three major inflammatory skin conditions combined —\nseborrheic dermatitis, eczema, and plaque psoriasis\nWESTLAKE VILLAGE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arcutis\nBiotherapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=eUctDDvFUqBmS7BJXTMMt8Xl9c9SH1KXJmeBWbv89P_q9ONTaotVIY_BsyQHKZ4tHuTMy97PJa7E0XAads-eDTQXbuPh3BcMvHa1UtdapsT0MMwKzkox4vVvzMjRBTm1qwhLhDSBUroa4BNrKhjiXJlB33nXHOiG-GmgEI7EsoOaJq_vBByQF3TrrVViRA4OgPHq7UJCgtLpM6U4AtwTVnpiyCMhRVL0IGfgrfuoUp1ZzAZ3yTwsBd8NuW6KIqNVFcXtW2zuV5ACuTngX3OlQLtkOiobpELcqv8RiT3bF-AehI2AFIjX5xbwg5z439QMCMVJUyXtk_nS8otJW8rK9ga9XxIdJwsrUzVa5UdAVNXPFthT2Zird2TUFG7pbn0C92ozpGzsLntrA6R8cXhudV31qh1IWRRRQIOu5vSB4XahsjeNxNYitiSPt9wikOKsISexDRuHnA7l4fcJkHHsMeL-My4AUuzaSIg6zeyMgTg5ySf4eH24HE5Awkjfw4iZo7sTrRVBVKsxfyZYcWlZElzS0HcUoX0fM9sXQEywAqet329efZ91yr-SNs2AApapTmNs8GK_xLgFsiIr3XMmBxcd85sipe_Odq0SLhhLBa-bku6IHP0lywcKUbJ8f9pR1cfF2v20cyVSSo3Lw4Wi8w==) (Nasdaq: ARQT\n(https://www.globenewswire.com/Tracker?data=oSX6M9_pDMNeYAgvTE-yCPZoqoJFCYbmFpX7nUijOYTkFXLInJVAT7PbB0d4Y-khllehvOM7_r1TPFQ6YktgDI7lojtgnoL_pWc0ataaWyo=)),\na commercial-stage biopharmaceutical company focused on developing meaningful\ninnovations in immuno-dermatology, today announced that World Champion gymnast\nSimone Biles has partnered with the company to launch its Skin to Believe In\nawareness campaign. The campaign encourages the approximately 36 million\nAmericans living with inflammatory skin conditions, such as seborrheic\ndermatitis and atopic dermatitis (the most common form of eczema), to talk\nwith their doctor about long-term, steroid-free, topical treatment options for\ntheir chronic skin diseases.\n\nThrough the Skin to Believe In awareness campaign, Simone shares her personal\njourney of working with a healthcare provider to better understand and manage\nher seborrheic dermatitis and eczema, including using ZORYVE(®) (roflumilast)\nfoam and cream. Like many others, she spent years trying a range of\nover-the-counter products in search of relief from her symptoms before finding\na steroid-free option that worked for her and fit into her routine. Her story\nhighlights the persistent and profound impact of these conditions for\nsufferers — including itching and flaking — and the importance of finding\nsolutions for clearer skin.\n\n“A couple of years ago I started noticing flakes and itching on my scalp —\nespecially on the crown of my head. At first, I thought it was a lot of\ndandruff, then I worried it might be something contagious. I also had patches\nof dry, itchy skin that kept appearing on my arms, and I wondered if the two\nwere related. I tried over-the-counter products like shampoos and creams, but\nthose didn’t work for me,” said Simone Biles. “Dealing with flakes in my\nhair was frustrating and made me feel uncomfortable, so I spoke with my\ndermatologist who diagnosed me with seborrheic dermatitis on my face and scalp\nand eczema on my arms. She recommended ZORYVE foam for my seborrheic\ndermatitis and ZORYVE cream for my eczema. I like ZORYVE because it is not a\nsteroid, pill, injection, or shampoo and it's easy to use, not greasy, and\nfits into my routine. Using ZORYVE reduced the flakes and itching on my scalp,\nwhich bothered me the most, and the eczema spots on my arms are also clearer,\ntoo.”\n\n(https://www.globenewswire.com/Tracker?data=nQRXkiQU323BitnH5r2nNucJEG_DVT1brtStyfvJBf8LBN13E_SRsAFtMSu5S7ojZI5jef1f00s-rS5-RVo8COz-1Nl_JdhrsLA6nArDjVo=)\n\nA Media Snippet accompanying this announcement is available by clicking on\nthis link.\n(https://www.globenewswire.com/Tracker?data=5NXUtEAk7zyTbYMYysAsGejY-DxvvbN3K8EZ0KnP13NTS76TN750-dUqwALpz_8hPnJ637WWfcKMxUuiPiQI5p9lxxxzhxPoDRxT5GFn2t9k6ajhLJt5iwFu-igqqs3WsnB6auWOK6b23kax6210MxXrl5ZFPeB3JEbhBqF7IpK35s3C7Vy4DoVSLuDJH6iDHmTZhP_M5tirowRn40tNHn1DPcXHXss1JovRCtHMsfs=)\n\n“For years, conditions like seborrheic dermatitis and eczema could require\nmultiple treatments, complex application schedules, and cycles of on and off\nuse due to the limitations of the treatments. Now, we have access to\ninnovative prescription treatments like ZORYVE that target the underlying\ninflammation driving these conditions, allowing us to improve symptoms,\" said\nDr. Angela J. Lamb, board-certified dermatologist. “ZORYVE is a once-daily,\nsteroid-free PDE4 inhibitor available in both foam and cream formulations that\nare non-greasy and don’t contain harmful ingredients that can disrupt the\nskin barrier. Finding solutions that can be used anywhere on the skin and\ncontinuously for any duration are important for long-term management of these\nchronic skin conditions.\"\n\nZORYVE foam 0.3% is indicated for the treatment of seborrheic dermatitis in\nadults and children 9 years of age and older. ZORYVE foam provides rapid\ndisease clearance and significant reduction in itch, with 77% of the 458\nindividuals using ZORYVE foam achieving clear or almost clear skin after 8\nweeks of treatment compared to 53% of the 225 people using inactive foam in\ncombined clinical trials.\n\nZORYVE cream 0.15% is indicated for the treatment of atopic dermatitis\n(eczema) in adults and children 6 years of age and older. In combined clinical\ntrials of over 1,300 people, ZORYVE rapidly improved eczema symptoms such as\nredness, itching, and rash with once-daily treatment — with nearly a third\n(31% of the 884 people) achieving clear or almost clear skin at 4 weeks with\nZORYVE cream compared to 14% of the 453 people using inactive cream, and many\npatients experiencing reduction in itch within 24 hours of the first\napplication.\n\n\"As one of the most recognized athletes in the world, Simone Biles understands\nthe significant challenges of living with a visible skin condition,\" said\nFrank Watanabe, president and CEO of Arcutis. \"By sharing her story, she is\nhelping to empower others to take control of their skin health by speaking\nwith their healthcare provider about advanced, targeted treatment options like\nZORYVE. This awareness campaign reinforces Arcutis’ commitment to delivering\ninnovative therapies for inflammatory skin conditions, including seborrheic\ndermatitis and eczema, with flexible solutions designed to meet patients’\nneeds from head to toe.\"\n\n“I’ve learned that we can’t fix every problem on our own and it’s OK\nto seek help,” continued Biles. “I believe how you care for yourself\nreflects how you carry yourself, and by partnering with Arcutis on this\nawareness campaign I believe we can break the stigma associated with chronic\nskin conditions by helping people feel empowered to speak with a healthcare\nprovider about their symptoms so that they can find a treatment that works for\nthem.”\n\nZORYVE is backed by robust clinical evidence, including eight pivotal trials\ninvolving approximately 4,200 participants. These studies consistently\ndemonstrate that ZORYVE cream and foam are well tolerated. The most common\nside effects with ZORYVE cream 0.15% for eczema (atopic dermatitis) are\nheadache, nausea, application site pain, and diarrhea. The most common side\neffects with ZORYVE foam 0.3% for seborrheic dermatitis are common cold,\nnausea, and headache. The adverse event profiles of ZORYVE cream and ZORYVE\nfoam in the long-term studies with up to a year of treatment were consistent\nwith those seen in the clinical studies.\n\nFor more information on ZORYVE cream and foam, including full prescribing\ninformation, please visit ZORYVE.com\n(https://www.globenewswire.com/Tracker?data=AyCvHrHI2D7LSRIcThKzxbsbi6p5ex0us-igv0RX3SOLArer7_DYiBZNSuZTEhxXCDaEppfWm82kjg3p38geFiMyj5IUEsc_51qpQCXECfAFm9FToFb2aefl-3Sz7saD48e1XIxjw8TYC43B3gUPCVKs5jSx5frOq2sFX3UtF1wDiDDnXWemaL02gv6vMcPL).\n\nAbout ZORYVE(®) (roflumilast)\nZORYVE is the number one prescribed branded topical therapy across three major\ninflammatory dermatoses combined — atopic dermatitis, seborrheic dermatitis,\nand plaque psoriasis. ZORYVE is a topical formulation of roflumilast, an\nadvanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor.\nInhibiting PDE4, an intracellular enzyme that is an established target in\ndermatology, decreases the production of pro-inflammatory mediators. This\ndecreases inflammation in the skin and balances the skin’s immune system.\n\nDemonstrating both clinical impact and broad industry recognition, ZORYVE has\nbeen honored with multiple prestigious awards and recommendations. ZORYVE was\nawarded by Allure with the \"2025 Best of Beauty Breakthrough Award,\" making\nit the first FDA-approved medication for atopic dermatitis, plaque psoriasis,\nand seborrheic dermatitis to win this prominent award. ZORYVE cream 0.3% and\nZORYVE foam 0.3% were also awarded the National Psoriasis Foundation’s Seal\nof Recognition — the first FDA-approved prescription brand to receive the\nhonor. Additionally, the American Academy of Dermatology (AAD) issued a strong\nrecommendation for the use of ZORYVE cream 0.15% in adult patients with mild\nto moderate atopic dermatitis, according to updated guidelines released in\nJune 2025. In 2024, ZORYVE cream 0.15% was awarded Glamour’s Beauty and\nWellness Award for “Best Eczema Product.”\n\nAbout the Skin to Believe In Awareness Campaign\nThe Skin to Believe In awareness campaign encourages people living with\ninflammatory skin conditions, including seborrheic dermatitis and eczema, to\nbelieve that relief is possible. The campaign empowers people to take the\nmeaningful step of having a conversation with a healthcare provider about\ntreatment options that fit seamlessly into their daily routine.\n\nINDICATIONS\nZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate\natopic dermatitis in adult and pediatric patients 6 years of age and older.\n\nZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis,\nincluding intertriginous areas, in adult and pediatric patients 2 years of age\nand older.\n\nZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate\natopic dermatitis in pediatric patients ages 2 to 5 years of age.\n\nZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis\nof the scalp and body in adult and pediatric patients 12 years of age and\nolder.\n\nZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic\ndermatitis in adult and pediatric patients 9 years of age and older.\n\nIMPORTANT SAFETY INFORMATION\nZORYVE is contraindicated in patients with moderate to severe liver impairment\n(Child-Pugh B or C).\n\nFlammability: The propellants in ZORYVE foam are flammable. Avoid fire,\nflame, and smoking during and immediately following application.\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for\npatients with atopic dermatitis 6 years of age or older were headache (2.9%),\nnausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting\n(1.5%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for\nplaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%),\nnausea (1.2%), application site pain (1.0%), upper respiratory tract infection\n(1.0%), and urinary tract infection (1.0%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for\npediatric patients with atopic dermatitis 2 to 5 years of age were upper\nrespiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis\n(1.6%), conjunctivitis (1.4%), and headache (1.1%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for\nplaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and\nnasopharyngitis (1.3%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for\nseborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache\n(1.1%).\n\nPlease see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=BpB8DZZuTaDqBzoCv227I6zklerelzE7yr0fsZ652-7pEz1MO_qtRKrhusQzmCtCPCz81Fukrs1Yz_9UnMIEd0LOaBdOYftZl_KuXFwSkzgcAjrri-BnXHeh3YfiOqAN)\nfor ZORYVE cream and full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=BpB8DZZuTaDqBzoCv227I6zklerelzE7yr0fsZ652-4MvAVfOhoci2IC13tW20CDusksXmtbLyKTDDLAfYstUbXTL8OczXw5XRDSDDJUMRUidilKo-ix7RRkaCDtxvdW)\nfor ZORYVE foam.\n\nZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal\nuse.\n\nAbout Arcutis\nArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical\ndermatology company delivering meaningful innovation to address the needs of\nindividuals living with chronic inflammatory skin diseases. Over the past\ndecade, Arcutis has successfully developed a robust portfolio of advanced\ntargeted topicals approved to treat three major inflammatory skin diseases,\ndriven by a commitment to solving the most persistent patient challenges in\ndermatology. Arcutis’ unique dermatology development platform, built on\nestablished scientific pathways and coupled with deep clinical dermatology and\ncommercial expertise, enables us to efficiently develop, scale, and deliver\nour differentiated therapies while advancing a growing pipeline across a range\nof inflammatory dermatological conditions. For more information,\nvisit www.arcutis.com or follow Arcutis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=WLj83wgJ6F37eILK80l2PbnxWW-FvefocjdN71E3NRxfZZkuuTK-aZKQV2VOev39JMykPZrd2FzRM1AqiEFKA4ZQiJkyKBodfwaJu0gHhldhcAjpGX2bESnWXTz_53po),\nFacebook\n(https://www.globenewswire.com/Tracker?data=zht8IA0V2E9cmKvazCOQOllLYAROFqB7lnyTtPCbQd-BLqAoKYXKKF35rTEwsa5V2KT4J-CzW-YnZeu6O7-t_00E_O1sxZoxFW7YGJ4LfTzIbyOAcEh-hLraULukm4x9apqGayA_RMf3irX0LeVWvg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=EFFIbp9Z6ZCYiZXFn2QBzE25auM6JGyTstuRBQzuGa9ny1nHvwddpjAXM2l_S2hkxZBq5lHlccueG7HxrOJYkEXUbZnJSsZhZaTnZ1RTA_k=),\nand X\n(https://www.globenewswire.com/Tracker?data=Heav5WuqPdY7v7ZaqgFVTdA7kiEeMne8hcXzCm2cgr3tSxgOcWTv6NIt7dgH2801CNL7n2S2HCD933brs29JuQ==).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. For example, statements contained\nin this press release regarding matters that are not historical facts are\nforward-looking statements. These statements are based on the Company’s\ncurrent beliefs and expectations. Such forward-looking statements include, but\nare not limited to, statements regarding the potential of ZORYVE cream and\nfoam to simplify disease management for care of atopic dermatitis and\nseborrheic dermatitis, or the potential of real-world use results of ZORYVE on\nindividual patients. These statements are subject to substantial known and\nunknown risks, uncertainties and other factors that may cause our actual\nresults, levels of activity, performance, or achievements to be materially\ndifferent from the information expressed or implied by these forward-looking\nstatements. Risks and uncertainties that may cause our actual results to\ndiffer include risks inherent in our business, reimbursement and access to our\nproducts, the impact of competition and other important factors discussed in\nthe “Risk Factors” section of our Form 10-K filed with the U.S. Securities\nand Exchange Commission (SEC) on February 25, 2026, as well as any subsequent\nfilings with the SEC. Any forward-looking statements that the company makes in\nthis press release are made pursuant to the Private Securities Litigation\nReform Act of 1995, as amended, and speak only as of the date of this press\nrelease. Except as required by law, we undertake no obligation to revise or\nupdate information herein to reflect events or circumstances in the future,\neven if new information becomes available.\n\nContacts:\nMedia\nAmanda Sheldon, Head of Corporate Communications\nmedia@arcutis.com\n\nInvestors\nBrian Schoelkopf, Head of Investor Relations\nir@arcutis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b166f47-afb1-44f1-91be-2d73e97c0ec3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX604n8k-20260929","title":"Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options","author":"Globe Newswire","ticker":"ARQT","created":"2026-09-29T13:15:00.224Z","tickers":["ARQT"],"exchange":"NASDAQ","article_body":"* Simone Biles opens up about her experience managing the symptoms of these\nconditions and encourages long-term control of skin health\n* Biles’ treatment, ZORYVE(®) (roflumilast), is the #1 prescribed branded\ntopical therapy for three major inflammatory skin conditions combined —\nseborrheic dermatitis, eczema, and plaque psoriasis\nWESTLAKE VILLAGE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arcutis\nBiotherapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=eUctDDvFUqBmS7BJXTMMt8Xl9c9SH1KXJmeBWbv89P_q9ONTaotVIY_BsyQHKZ4tHuTMy97PJa7E0XAads-eDTQXbuPh3BcMvHa1UtdapsT0MMwKzkox4vVvzMjRBTm1qwhLhDSBUroa4BNrKhjiXJlB33nXHOiG-GmgEI7EsoOaJq_vBByQF3TrrVViRA4OgPHq7UJCgtLpM6U4AtwTVnpiyCMhRVL0IGfgrfuoUp1ZzAZ3yTwsBd8NuW6KIqNVFcXtW2zuV5ACuTngX3OlQLtkOiobpELcqv8RiT3bF-AehI2AFIjX5xbwg5z439QMCMVJUyXtk_nS8otJW8rK9ga9XxIdJwsrUzVa5UdAVNXPFthT2Zird2TUFG7pbn0C92ozpGzsLntrA6R8cXhudV31qh1IWRRRQIOu5vSB4XahsjeNxNYitiSPt9wikOKsISexDRuHnA7l4fcJkHHsMeL-My4AUuzaSIg6zeyMgTg5ySf4eH24HE5Awkjfw4iZo7sTrRVBVKsxfyZYcWlZElzS0HcUoX0fM9sXQEywAqet329efZ91yr-SNs2AApapTmNs8GK_xLgFsiIr3XMmBxcd85sipe_Odq0SLhhLBa-bku6IHP0lywcKUbJ8f9pR1cfF2v20cyVSSo3Lw4Wi8w==) (Nasdaq: ARQT\n(https://www.globenewswire.com/Tracker?data=oSX6M9_pDMNeYAgvTE-yCPZoqoJFCYbmFpX7nUijOYTkFXLInJVAT7PbB0d4Y-khllehvOM7_r1TPFQ6YktgDI7lojtgnoL_pWc0ataaWyo=)),\na commercial-stage biopharmaceutical company focused on developing meaningful\ninnovations in immuno-dermatology, today announced that World Champion gymnast\nSimone Biles has partnered with the company to launch its Skin to Believe In\nawareness campaign. The campaign encourages the approximately 36 million\nAmericans living with inflammatory skin conditions, such as seborrheic\ndermatitis and atopic dermatitis (the most common form of eczema), to talk\nwith their doctor about long-term, steroid-free, topical treatment options for\ntheir chronic skin diseases.\n\nThrough the Skin to Believe In awareness campaign, Simone shares her personal\njourney of working with a healthcare provider to better understand and manage\nher seborrheic dermatitis and eczema, including using ZORYVE(®) (roflumilast)\nfoam and cream. Like many others, she spent years trying a range of\nover-the-counter products in search of relief from her symptoms before finding\na steroid-free option that worked for her and fit into her routine. Her story\nhighlights the persistent and profound impact of these conditions for\nsufferers — including itching and flaking — and the importance of finding\nsolutions for clearer skin.\n\n“A couple of years ago I started noticing flakes and itching on my scalp —\nespecially on the crown of my head. At first, I thought it was a lot of\ndandruff, then I worried it might be something contagious. I also had patches\nof dry, itchy skin that kept appearing on my arms, and I wondered if the two\nwere related. I tried over-the-counter products like shampoos and creams, but\nthose didn’t work for me,” said Simone Biles. “Dealing with flakes in my\nhair was frustrating and made me feel uncomfortable, so I spoke with my\ndermatologist who diagnosed me with seborrheic dermatitis on my face and scalp\nand eczema on my arms. She recommended ZORYVE foam for my seborrheic\ndermatitis and ZORYVE cream for my eczema. I like ZORYVE because it is not a\nsteroid, pill, injection, or shampoo and it's easy to use, not greasy, and\nfits into my routine. Using ZORYVE reduced the flakes and itching on my scalp,\nwhich bothered me the most, and the eczema spots on my arms are also clearer,\ntoo.”\n\n(https://www.globenewswire.com/Tracker?data=nQRXkiQU323BitnH5r2nNucJEG_DVT1brtStyfvJBf8LBN13E_SRsAFtMSu5S7ojZI5jef1f00s-rS5-RVo8COz-1Nl_JdhrsLA6nArDjVo=)\n\nA Media Snippet accompanying this announcement is available by clicking on\nthis link.\n(https://www.globenewswire.com/Tracker?data=5NXUtEAk7zyTbYMYysAsGejY-DxvvbN3K8EZ0KnP13NTS76TN750-dUqwALpz_8hPnJ637WWfcKMxUuiPiQI5p9lxxxzhxPoDRxT5GFn2t9k6ajhLJt5iwFu-igqqs3WsnB6auWOK6b23kax6210MxXrl5ZFPeB3JEbhBqF7IpK35s3C7Vy4DoVSLuDJH6iDHmTZhP_M5tirowRn40tNHn1DPcXHXss1JovRCtHMsfs=)\n\n“For years, conditions like seborrheic dermatitis and eczema could require\nmultiple treatments, complex application schedules, and cycles of on and off\nuse due to the limitations of the treatments. Now, we have access to\ninnovative prescription treatments like ZORYVE that target the underlying\ninflammation driving these conditions, allowing us to improve symptoms,\" said\nDr. Angela J. Lamb, board-certified dermatologist. “ZORYVE is a once-daily,\nsteroid-free PDE4 inhibitor available in both foam and cream formulations that\nare non-greasy and don’t contain harmful ingredients that can disrupt the\nskin barrier. Finding solutions that can be used anywhere on the skin and\ncontinuously for any duration are important for long-term management of these\nchronic skin conditions.\"\n\nZORYVE foam 0.3% is indicated for the treatment of seborrheic dermatitis in\nadults and children 9 years of age and older. ZORYVE foam provides rapid\ndisease clearance and significant reduction in itch, with 77% of the 458\nindividuals using ZORYVE foam achieving clear or almost clear skin after 8\nweeks of treatment compared to 53% of the 225 people using inactive foam in\ncombined clinical trials.\n\nZORYVE cream 0.15% is indicated for the treatment of atopic dermatitis\n(eczema) in adults and children 6 years of age and older. In combined clinical\ntrials of over 1,300 people, ZORYVE rapidly improved eczema symptoms such as\nredness, itching, and rash with once-daily treatment — with nearly a third\n(31% of the 884 people) achieving clear or almost clear skin at 4 weeks with\nZORYVE cream compared to 14% of the 453 people using inactive cream, and many\npatients experiencing reduction in itch within 24 hours of the first\napplication.\n\n\"As one of the most recognized athletes in the world, Simone Biles understands\nthe significant challenges of living with a visible skin condition,\" said\nFrank Watanabe, president and CEO of Arcutis. \"By sharing her story, she is\nhelping to empower others to take control of their skin health by speaking\nwith their healthcare provider about advanced, targeted treatment options like\nZORYVE. This awareness campaign reinforces Arcutis’ commitment to delivering\ninnovative therapies for inflammatory skin conditions, including seborrheic\ndermatitis and eczema, with flexible solutions designed to meet patients’\nneeds from head to toe.\"\n\n“I’ve learned that we can’t fix every problem on our own and it’s OK\nto seek help,” continued Biles. “I believe how you care for yourself\nreflects how you carry yourself, and by partnering with Arcutis on this\nawareness campaign I believe we can break the stigma associated with chronic\nskin conditions by helping people feel empowered to speak with a healthcare\nprovider about their symptoms so that they can find a treatment that works for\nthem.”\n\nZORYVE is backed by robust clinical evidence, including eight pivotal trials\ninvolving approximately 4,200 participants. These studies consistently\ndemonstrate that ZORYVE cream and foam are well tolerated. The most common\nside effects with ZORYVE cream 0.15% for eczema (atopic dermatitis) are\nheadache, nausea, application site pain, and diarrhea. The most common side\neffects with ZORYVE foam 0.3% for seborrheic dermatitis are common cold,\nnausea, and headache. The adverse event profiles of ZORYVE cream and ZORYVE\nfoam in the long-term studies with up to a year of treatment were consistent\nwith those seen in the clinical studies.\n\nFor more information on ZORYVE cream and foam, including full prescribing\ninformation, please visit ZORYVE.com\n(https://www.globenewswire.com/Tracker?data=AyCvHrHI2D7LSRIcThKzxbsbi6p5ex0us-igv0RX3SOLArer7_DYiBZNSuZTEhxXCDaEppfWm82kjg3p38geFiMyj5IUEsc_51qpQCXECfAFm9FToFb2aefl-3Sz7saD48e1XIxjw8TYC43B3gUPCVKs5jSx5frOq2sFX3UtF1wDiDDnXWemaL02gv6vMcPL).\n\nAbout ZORYVE(®) (roflumilast)\nZORYVE is the number one prescribed branded topical therapy across three major\ninflammatory dermatoses combined — atopic dermatitis, seborrheic dermatitis,\nand plaque psoriasis. ZORYVE is a topical formulation of roflumilast, an\nadvanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor.\nInhibiting PDE4, an intracellular enzyme that is an established target in\ndermatology, decreases the production of pro-inflammatory mediators. This\ndecreases inflammation in the skin and balances the skin’s immune system.\n\nDemonstrating both clinical impact and broad industry recognition, ZORYVE has\nbeen honored with multiple prestigious awards and recommendations. ZORYVE was\nawarded by Allure with the \"2025 Best of Beauty Breakthrough Award,\" making\nit the first FDA-approved medication for atopic dermatitis, plaque psoriasis,\nand seborrheic dermatitis to win this prominent award. ZORYVE cream 0.3% and\nZORYVE foam 0.3% were also awarded the National Psoriasis Foundation’s Seal\nof Recognition — the first FDA-approved prescription brand to receive the\nhonor. Additionally, the American Academy of Dermatology (AAD) issued a strong\nrecommendation for the use of ZORYVE cream 0.15% in adult patients with mild\nto moderate atopic dermatitis, according to updated guidelines released in\nJune 2025. In 2024, ZORYVE cream 0.15% was awarded Glamour’s Beauty and\nWellness Award for “Best Eczema Product.”\n\nAbout the Skin to Believe In Awareness Campaign\nThe Skin to Believe In awareness campaign encourages people living with\ninflammatory skin conditions, including seborrheic dermatitis and eczema, to\nbelieve that relief is possible. The campaign empowers people to take the\nmeaningful step of having a conversation with a healthcare provider about\ntreatment options that fit seamlessly into their daily routine.\n\nINDICATIONS\nZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate\natopic dermatitis in adult and pediatric patients 6 years of age and older.\n\nZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis,\nincluding intertriginous areas, in adult and pediatric patients 2 years of age\nand older.\n\nZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate\natopic dermatitis in pediatric patients ages 2 to 5 years of age.\n\nZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis\nof the scalp and body in adult and pediatric patients 12 years of age and\nolder.\n\nZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic\ndermatitis in adult and pediatric patients 9 years of age and older.\n\nIMPORTANT SAFETY INFORMATION\nZORYVE is contraindicated in patients with moderate to severe liver impairment\n(Child-Pugh B or C).\n\nFlammability: The propellants in ZORYVE foam are flammable. Avoid fire,\nflame, and smoking during and immediately following application.\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for\npatients with atopic dermatitis 6 years of age or older were headache (2.9%),\nnausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting\n(1.5%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for\nplaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%),\nnausea (1.2%), application site pain (1.0%), upper respiratory tract infection\n(1.0%), and urinary tract infection (1.0%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for\npediatric patients with atopic dermatitis 2 to 5 years of age were upper\nrespiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis\n(1.6%), conjunctivitis (1.4%), and headache (1.1%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for\nplaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and\nnasopharyngitis (1.3%).\n\nThe most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for\nseborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache\n(1.1%).\n\nPlease see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=BpB8DZZuTaDqBzoCv227I6zklerelzE7yr0fsZ652-7pEz1MO_qtRKrhusQzmCtCPCz81Fukrs1Yz_9UnMIEd0LOaBdOYftZl_KuXFwSkzgcAjrri-BnXHeh3YfiOqAN)\nfor ZORYVE cream and full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=BpB8DZZuTaDqBzoCv227I6zklerelzE7yr0fsZ652-4MvAVfOhoci2IC13tW20CDusksXmtbLyKTDDLAfYstUbXTL8OczXw5XRDSDDJUMRUidilKo-ix7RRkaCDtxvdW)\nfor ZORYVE foam.\n\nZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal\nuse.\n\nAbout Arcutis\nArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical\ndermatology company delivering meaningful innovation to address the needs of\nindividuals living with chronic inflammatory skin diseases. Over the past\ndecade, Arcutis has successfully developed a robust portfolio of advanced\ntargeted topicals approved to treat three major inflammatory skin diseases,\ndriven by a commitment to solving the most persistent patient challenges in\ndermatology. Arcutis’ unique dermatology development platform, built on\nestablished scientific pathways and coupled with deep clinical dermatology and\ncommercial expertise, enables us to efficiently develop, scale, and deliver\nour differentiated therapies while advancing a growing pipeline across a range\nof inflammatory dermatological conditions. For more information,\nvisit www.arcutis.com or follow Arcutis on LinkedIn\n(https://www.globenewswire.com/Tracker?data=WLj83wgJ6F37eILK80l2PbnxWW-FvefocjdN71E3NRxfZZkuuTK-aZKQV2VOev39JMykPZrd2FzRM1AqiEFKA4ZQiJkyKBodfwaJu0gHhldhcAjpGX2bESnWXTz_53po),\nFacebook\n(https://www.globenewswire.com/Tracker?data=zht8IA0V2E9cmKvazCOQOllLYAROFqB7lnyTtPCbQd-BLqAoKYXKKF35rTEwsa5V2KT4J-CzW-YnZeu6O7-t_00E_O1sxZoxFW7YGJ4LfTzIbyOAcEh-hLraULukm4x9apqGayA_RMf3irX0LeVWvg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=EFFIbp9Z6ZCYiZXFn2QBzE25auM6JGyTstuRBQzuGa9ny1nHvwddpjAXM2l_S2hkxZBq5lHlccueG7HxrOJYkEXUbZnJSsZhZaTnZ1RTA_k=),\nand X\n(https://www.globenewswire.com/Tracker?data=Heav5WuqPdY7v7ZaqgFVTdA7kiEeMne8hcXzCm2cgr3tSxgOcWTv6NIt7dgH2801CNL7n2S2HCD933brs29JuQ==).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. For example, statements contained\nin this press release regarding matters that are not historical facts are\nforward-looking statements. These statements are based on the Company’s\ncurrent beliefs and expectations. Such forward-looking statements include, but\nare not limited to, statements regarding the potential of ZORYVE cream and\nfoam to simplify disease management for care of atopic dermatitis and\nseborrheic dermatitis, or the potential of real-world use results of ZORYVE on\nindividual patients. These statements are subject to substantial known and\nunknown risks, uncertainties and other factors that may cause our actual\nresults, levels of activity, performance, or achievements to be materially\ndifferent from the information expressed or implied by these forward-looking\nstatements. Risks and uncertainties that may cause our actual results to\ndiffer include risks inherent in our business, reimbursement and access to our\nproducts, the impact of competition and other important factors discussed in\nthe “Risk Factors” section of our Form 10-K filed with the U.S. Securities\nand Exchange Commission (SEC) on February 25, 2026, as well as any subsequent\nfilings with the SEC. Any forward-looking statements that the company makes in\nthis press release are made pursuant to the Private Securities Litigation\nReform Act of 1995, as amended, and speak only as of the date of this press\nrelease. Except as required by law, we undertake no obligation to revise or\nupdate information herein to reflect events or circumstances in the future,\neven if new information becomes available.\n\nContacts:\nMedia\nAmanda Sheldon, Head of Corporate Communications\nmedia@arcutis.com\n\nInvestors\nBrian Schoelkopf, Head of Investor Relations\nir@arcutis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b166f47-afb1-44f1-91be-2d73e97c0ec3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T13:15:00.305383655Z","server_sent_at_ms":1790687700305},"received_at":"2026-09-29T13:15:00.552Z","source_url":null},"analysis":{"id":"144275","press_release_id":"155551","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Arcutis Biotherapeutics partnered with Olympic gymnast Simone Biles to launch the Skin to Believe In awareness campaign for seborrheic dermatitis and eczema.\n\nBiles discloses she uses ZORYVE foam and cream, and the release notes ZORYVE is the #1 prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined.\n\nThe campaign targets the roughly 36 million Americans with inflammatory skin conditions; it is a marketing catalyst for prescriptions rather than new clinical or financial news.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Simone Biles becomes ZORYVE's celebrity face -- watch for a lift in topical prescription trends."},"keyFigures":{"customDimensions":{"pivotal_trials":"eight pivotal trials, approximately 4,200 participants","zoryve_foam_clear_skin":"77% of 458 patients clear/almost clear at 8 weeks vs 53% of 225 on vehicle","addressable_patients_us":"approximately 36 million Americans with inflammatory skin conditions","zoryve_cream_clear_skin":"31% of 884 patients clear/almost clear at 4 weeks vs 14% of 453 on vehicle"}},"quotedText":"As one of the most recognized athletes in the world, Simone Biles understands the significant challenges of living with a visible skin condition","namedEntities":{"people":[{"name":"Simone Biles","role":"World Champion gymnast, campaign partner"},{"name":"Frank Watanabe","role":"President and CEO of Arcutis"},{"name":"Dr. Angela J. Lamb","role":"board-certified dermatologist"}],"products":["ZORYVE (roflumilast) foam 0.3%","ZORYVE cream 0.15%","Skin to Believe In campaign"],"companies":[{"name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Celebrity brand-awareness campaign for already-commercialized products; a modest positive for ZORYVE prescription demand but no new clinical, financial, or regulatory information."},"tickerRelevance":{"others":[],"primary":"ARQT"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap commercial biotech","eventGravity":"marketing/awareness campaign","celebrityBoost":"Simone Biles raises retail visibility","financialMateriality":"low"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Arcutis Biotherapeutics partnered with Olympic gymnast Simone Biles to launch the Skin to Believe In awareness campaign for seborrheic dermatitis and eczema.\n\nBiles discloses she uses ZORYVE foam and cream, and the release notes ZORYVE is the #1 prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined.\n\nThe campaign targets the roughly 36 million Americans with inflammatory skin conditions; it is a marketing catalyst for prescriptions rather than new clinical or financial news.","key_figures":{"customDimensions":{"pivotal_trials":"eight pivotal trials, approximately 4,200 participants","zoryve_foam_clear_skin":"77% of 458 patients clear/almost clear at 8 weeks vs 53% of 225 on vehicle","addressable_patients_us":"approximately 36 million Americans with inflammatory skin conditions","zoryve_cream_clear_skin":"31% of 884 patients clear/almost clear at 4 weeks vs 14% of 453 on vehicle"}},"named_entities":{"people":[{"name":"Simone Biles","role":"World Champion gymnast, campaign partner"},{"name":"Frank Watanabe","role":"President and CEO of Arcutis"},{"name":"Dr. Angela J. Lamb","role":"board-certified dermatologist"}],"products":["ZORYVE (roflumilast) foam 0.3%","ZORYVE cream 0.15%","Skin to Believe In campaign"],"companies":[{"name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T13:15:06.296Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap commercial biotech","eventGravity":"marketing/awareness campaign","celebrityBoost":"Simone Biles raises retail visibility","financialMateriality":"low"}},"durationMs":5693,"modelName":"glm-5.3-flashx"}}